Omri Zveik

Dr. Omri Zveik

Hadassah Medical Center, Jerusalem, Southern, Israel
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
LBLivnat Brill
Livnat Brill
ARAriel Rechtman
Ariel Rechtman
OZOmri Zveik
Omri Zveik
NHNitzan Haham
Nitzan Haham
EOEsther Oiknine-Djian
Esther Oiknine-Djian
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
The SARS-CoV-2 pandemic has presented a clinical concern for patients with multiple sclerosis (MS), whose mainstay treatment are immunosuppressive/immunomodulatory disease-modifying therapies.1 Most approved vaccines, including the messenger RNA vaccines, induce robust humoral and cellular immune responses against the virus spike protein2,3; however, it is still unknown whether SARS-CoV-2 vaccines confer sufficient protection in patients with MS treated with disease-modifying therapies.

12 July 2024 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
OZOmri Zveik
Omri Zveik
ARAriel Rechtman
Ariel Rechtman
TGTal Ganz
Tal Ganz
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
Background: Multiple sclerosis (MS) therapeutic goals have traditionally been dichotomized into two distinct avenues: immune-modulatory-centric interventions and pro-regenerative strategies. Oligodendrocyte progenitor cells (OPCs) were regarded for many years solely in concern to their potential to generate oligodendrocytes and myelin in the central nervous system (CNS). However, accumulating data elucidate the multifaceted roles of OPCs, including their immunomodulatory functions, positioning them as cardinal constituents of the CNS’s immune landscape. Main body: In this review, we will discuss how the two therapeutic approaches converge. We present a model by which (1) an inflammation is required for the appropriate pro-myelinating immune function of OPCs in the chronically inflamed CNS, and (2) the immune function of OPCs is crucial for their ability to differentiate and promote remyelination. This model highlights the reciprocal interactions between OPCs’ pro-myelinating and immune-modulating functions. Additionally, we review the specific effects of anti- and pro-inflammatory interventions on OPCs, suggesting that immunosuppression adversely affects OPCs’ differentiation and immune functions. Conclusion: We suggest a multi-systemic therapeutic approach, which necessitates not a unidimensional focus but a harmonious balance between OPCs’ pro-myelinating and immune-modulatory functions.

9 March 2022 in Glia
Verified
Journal Article
Open access
OZOmri Zveik
Omri Zveik
NFNina Fainstein
Nina Fainstein
ARAriel Rechtman
Ariel Rechtman
NHNitzan Haham
Nitzan Haham
TGTal Ganz
Tal Ganz
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
Oligodendrocyte progenitor cells (OPCs) are responsible for remyelination in the central nervous system (CNS) in health and disease. For patients with multiple sclerosis (MS), remyelination is not always successful, and the mechanisms differentiating successful from failed remyelination are not well-known. Growing evidence suggests an immune role for OPCs, in addition to their regenerative role; however, it is not clear if this helps or hinders the regenerative process. We studied the effect of cerebrospinal fluid (CSF) from relapsing MS (rMS) and progressive MS (pMS) patients on primary OPC differentiation and immune gene expression and function. We observed that CSF from either rMS or pMS patients has a differential effect on the ability of mice OPCs to differentiate into mature oligodendrocytes and to express immune functions. CSF of pMS patients impaired differentiation into mature oligodendrocytes. In addition, it led to decreased major histocompatibility complex class (MHC)-II expression, tumor necrosis factor (TNF)-alpha secretion, nuclear factor kappa-B (NF kappa B) activation, and less activation and proliferation of T cells. Our findings suggest that OPCs are not only responsible for remyelination, but they may also play an active role as innate immune cells in the CNS.

24 March 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
ARAriel Rechtman
Ariel Rechtman
LBLivnat Brill
Livnat Brill
OZOmri Zveik
Omri Zveik
BUBenjamin Uliel
Benjamin Uliel
NHNitzan Haham
Nitzan Haham
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
Background: Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS. MOGAD can present with a monophasic or relapsing disease course with distinct clinical manifestations.However, data on the disease course and disability outcomes of these patients are scarce. We aim to compare brain volumetric changes for MOGAD patients with different disease phenotypes and HCs. Methods: Brain magnetic resonance imaging (MRI) scans and clinical data were obtained for 22 MOGAD patients and 22 HCs. Volumetric brain information was determined using volBrain and MDbrain platforms. Results: We found decreased brain volume in MOGAD patients compared to HCs, as identified in volume of total brain, gray matter, white matter and deep gray matter (DGM) structures. In addition, we found significantly different volumetric changes between patients with relapsing and monophasic disease course, with significantly decreased volume of total brain and DGM, cerebellum and hippocampus in relapsing patients during the first year of diagnosis. A significant negative correlation was found between EDSS and volume of thalamus. Conclusions: Brain MRI analyses revealed volumetric differences between MOGAD patients and HCs, and between patients with different disease phenotypes. Decreased gray matter volume during the first year of diagnosis, especially in the cerebrum and hippocampus of MOGAD patients was associated with relapsing disease course.

24 March 2022 in Annals of Neurology
Verified
Journal Article
Open access
LBLivnat Brill
Livnat Brill
CRCatarina Raposo
Catarina Raposo
ARAriel Rechtman
Ariel Rechtman
OZOmri Zveik
Omri Zveik
NLNetta Levin
Netta Levin
AVAdi Vaknin-Dembinsky
Adi Vaknin-Dembinsky
The introduction of a third‐dose vaccination along with new variants of concern raises questions regarding serology and T‐cell responses in patients with multiple sclerosis (pwMS) treated with B‐cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS‐CoV‐2 mRNA vaccine in ocrelizumab‐treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab‐treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800

19 January 2024 in Immunology
Verified
Journal Article
Open access
OZOmri Zveik
Omri Zveik
ARAriel Rechtman
Ariel Rechtman
LBLivnat Brill
Livnat Brill
AVAdi Vaknin‐Dembinsky
Adi Vaknin‐Dembinsky
Oligodendrocyte progenitor cells (OPCs) were regarded for years solely for their regenerative role; however, their immune‐modulatory roles have gained much attention recently, particularly in the context of multiple sclerosis (MS). Despite extensive studies on OPCs, there are limited data elucidating the interactions between their intrinsic regenerative and immune functions, as well as their relationship with the inflamed central nervous system (CNS) environment, a key factor in MS pathology. We examined the effects of pro‐inflammatory cytokines, represented by interferon (IFN)‐γ and tumour necrosis factor (TNF)‐α, as well as anti‐inflammatory cytokines, represented by interleukin (IL)‐4 and IL‐10, on OPC differentiation and immune characteristics. Using primary cultures, enzyme‐linked immunosorbent assay and immunofluorescence stainings, we assessed differentiation capacity, phagocytic activity, major histocompatibility complex (MHC)‐II expression, and cytokine secretion. We observed that the anti‐inflammatory milieu (IL4 and IL10) reduced both OPC differentiation and immune functions. Conversely, exposure to TNF‐α led to intact differentiation, increased phagocytic activity, high levels of MHC‐II expression, and cytokines secretion. Those effects were attributed to signalling via TNF‐receptor‐2 and counteracted the detrimental effects of IFN‐γ on OPC differentiation. Our findings suggest that a pro‐regenerative, permissive inflammatory environment is needed for OPCs to execute both regenerative and immune‐modulatory functions.